Analysis of decrease in sensitivity in influenza A (H5N1) avian and human strains to neuraminidase inhibitors;Análisis de la disminución de la sensibilidad de las cepas gripales A (H5N1) aviares y humanas a los inhibidores de la neuraminidasa

Revista Espanola de Quimioterapia

Volumn 21, Issue 1, 2008, Pages 32-36

  Reina, Jordi ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Antiviral resistance; Avian influenza; H5N1; Neuraminidase inhibitors

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; AVIAN INFLUENZA; CLADISTICS; INFLUENZA VIRUS A H5N1; PANDEMIC; PHENOTYPE; REVIEW; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; DRUG RESISTANCE, VIRAL; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICROBIAL SENSITIVITY TESTS; MUTATION; NEURAMINIDASE;

EID: 46049085587     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. The Writing Committee of the World Health Organization (WHO) consultation on human influenza A/H5. N Engl J Med 2005;353:1374-85.
2. World Health Organization. WHO global influenza preparedness plan. The role of the WHO and recommendations for national measures before and during pandemics, 2005.
3. Plan nacional de preparación y respuesta ante una pandemia de gripe. Ministerio de Sanidad y Consumo, 2005.
4. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science 2003;302:1519-22.
5. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis 2003;46:1552-61.
6. Webby RJ, Perez DR, Coleman JS. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004;363:1099-103.
7. Reina J. Inhibidores de la neuraminidasa y su potencial utilización en la pandemia de gripe aviar. Med Clin (Barc) 2005;125: 780-3.
8. Li KS, Guan Y, Wang J, Smith GJD, Xu KM, Duan L, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004;430:209-13.
9. Reina J, Ortiz de Lejarazu R. Mecanismos de patogenicidad y adaptabilidad humana de las cepas gripales aviares A (H5N1). Rev Esp Quimioter 2005;18:273-80.
10. Guan Y, Peiris JS, Lipatov AS, Ellis TM, Dyrting KC, Krauss S, et al. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. Proc Natl Acad Sci USA 2002; 99:8950-5.
11. Shortridge K, Zhou N, Guan Y, Gao P, Ito T, Kawaoka Y, et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. Virology 1998;252:331-42.
12. Matrosovich M, Zhou N, Kawaoka Y, Webster RG. The surface glycoprotein of H5 influenza viruses isolated from humans, chickens and wild aquatic birds have distinguishable properties. J Virol 1999;73:1146-155.
13. World Health Organization. Avian influenza A (H5N1). Weekly Epidemiol Rev 2004;79:65-70.
14. Rameix-Welti MA, Agou F, Buchy P, Mardy S, Aubin JT, Veron M, et al. Natural variation can significatly alter sensitivity to oseltamivir of influenza A (H5N1) viruses. Antimicrob Agents Chemother 2006;50:3809-15.
15. De Clerq E, Neysts J. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharmacol Sci 2007;28:280-5.
16. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis J 2007;13:1354-7.
17. Govorkova EA, Ilyushina NA, Boltz DA, Douglas A, Yilmaz N, Webster RG. Efficacy of oseltamivir therapy in ferrets inoculated with different clases of H5N1 influenza virus. Antimicrob Agents Chemother 2007;51:1414-24
18. World Health Organization. Tamiflu resistance found in Egypt patients. Destacado en prensa el 22 de enero de 2007. En: http://www.emro.who.int/csr/ media/pdf/ai_press_22_01_07.pdf.
19. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguye KH, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.
20. McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 1996;225:240-2.
21. McKimm-Breschkin JL, Sahasrabushe A, Blick TJ, McDonald M, Colman PM, Hart GJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998;72:2456-62.
22. McKimm-Breschkin JL. Resistance of influenza viruses to neuraminidase inhibitors: a review. Antivir Res 2000;47:1-17.
23. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence and implications of drug resistance. Treat Respir Med 2005;4:107-16.
24. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, et al. Importance of neuraminidase active-site residues to the neuraminidasa inhibitor resistance of influenza viruses. J Virol 2006;80:8787-95.
25. McKimm-Breschkin JL, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, et al. Neuraminidase sequence analysis and susceptibilities of influienza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003;47:2264-72.
26. Colman PM. Influenza virus neuraminidase: structure, antibodies and inhibitors. Protein Sci 1994;3:1687-96.
27. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983;303:41-4.
28. Smith BJ, McKimm-Breschkin JL, McDonald M, Fernley RT, Varghese JN, Colman PM. Strutural studies of the resistance of influenza virus neuraminidase to inhibitors. Med Chem 2002;45:2207-12.
29. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005;49:4075-84.
30. Reina J. Peramivir. Un nuevo y potente inhibidor de la neuraminidase para el tratamiento de las infecciones gripales. Rev Esp Quimioter 2006;19:317-22.
31. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, et al. Detection of infuenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50: 2395-402.
32. Hurt AC, Selleck P, Komadina N, Shaw R, Brown I, Barr IG. Susceptibility of higly pathogenic A (H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007;73:228-31.